Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1Phase 2 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Noonan Syndrome 5 1

Interventions

pembrolizumab 80Carboplatin 73Paclitaxel 58Cisplatin 58Specimen Handling 56Magnetic Resonance Spectroscopy 56Gemcitabine 48Docetaxel 37Dexamethasone 37Oxaliplatin 34Fluorouracil 33Bevacizumab 33Pemetrexed 32Leucovorin 32Doxorubicin 32Cyclophosphamide 31durvalumab 29Radiotherapy 29Radiation 28Capecitabine 28Rituximab 25Letrozole 25Etoposide 24Nivolumab 23Irinotecan 23Vincristine 22Taxes 21Lenalidomide 21Prednisone 20Bortezomib 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Antineoplastic Agents × 30 days × Clear all
NCT05566795 2026-05-14

DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

Day One Biopharmaceuticals, Inc.

Phase 3 Active not recruiting
418 enrolled

Noonan Syndrome 5

Data powered by HemOnc (CC BY 4.0) Colophon âš¡